ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.71
-0.56%
US Tech 100
18,392.00
0.90%
S&P 500
5,307.01
-0.27%
US Dollar vs CAD
1.36746
-0.12%
Bitcoin
69,637.68
0.77%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Centessa Pharmaceuticals PLC (CNTA)

  7. Centessa Pharmaceuticals PLC (CNTA) News

CNTA Centessa Pharmaceuticals PLC

8.75
0.00 (0.00%)
Pre Market
Last Updated: 03:17:21
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Centessa Pharmaceuticals PLC CNTA NASDAQ Depository Receipt
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
0.00 0.00% 8.75 03:17:21
Open Price Low Price High Price Close Price Previous Close
8.75
more quote information »

Recent News

Date Time Source Heading
5/21/202407:45GLOBECentessa Pharmaceuticals to Participate in Upcoming Investor..
5/13/202415:32EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
5/13/202415:23EDGAR2Form 8-K - Current report
5/13/202415:10GLOBECentessa Pharmaceuticals Reports Financial Results and..
5/09/202407:01EDGAR2Form ARS - Annual Report to Security Holders
5/09/202407:00EDGAR2Form DEF 14A - Other definitive proxy statements
4/23/202420:36GLOBECentessa Pharmaceuticals Announces Pricing of $100 Million..
4/23/202415:17GLOBECentessa Pharmaceuticals Announces $100 Million Proposed..
4/22/202406:00GLOBECentessa Pharmaceuticals Announces Open IND for ORX750;..
3/28/202415:28GLOBECentessa Pharmaceuticals Reports Business Highlights and..
2/22/202407:00GLOBECentessa Pharmaceuticals to Participate in TD Cowen’s 44th..
2/09/202406:12EDGAR2Form 8-K - Current report
2/09/202406:00GLOBECentessa Pharmaceuticals to Present Additional 52-Weeks of..
2/02/202416:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/02/202416:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/02/202416:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/02/202416:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/02/202416:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/01/202415:07EDGAR2Form 144 - Report of proposed sale of securities
1/22/202407:00GLOBECentessa Pharmaceuticals to Participate in Upcoming Investor..
1/09/202406:56EDGAR2Form 8-K - Current report
1/02/202418:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/02/202418:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/02/202418:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/02/202418:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/02/202418:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/13/202307:00GLOBECentessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P...
12/11/202306:05EDGAR2Form 8-K - Current report
12/10/202311:05GLOBECentessa Pharmaceuticals Announces New Data from an..
11/27/202315:15GLOBEAnaptys Expands Immune Cell Modulator Pipeline with..
11/13/202315:22EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/13/202315:17EDGAR2Form 8-K - Current report
11/13/202315:05GLOBECentessa Pharmaceuticals Reports Financial Results and..
11/02/202308:09GLOBECentessa Pharmaceuticals to Present Additional 52-Weeks of..
10/31/202307:00GLOBECentessa Pharmaceuticals Announces Dosing of First Subject..
10/30/202307:00GLOBECentessa Pharmaceuticals to Participate in Upcoming Investor..
10/25/202308:49EDGAR2Form 8-K - Current report
10/25/202307:00GLOBECentessa Pharmaceuticals Announces Preclinical Data..
10/03/202316:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/03/202315:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/03/202315:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/03/202315:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/03/202315:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/03/202307:00GLOBECentessa Pharmaceuticals Announces Additions to Senior..
9/22/202315:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
9/20/202315:02EDGAR2Form 144 - Report of proposed sale of securities
9/01/202315:31EDGAR2Form 144 - Report of proposed sale of securities
8/31/202307:00GLOBECentessa Pharmaceuticals to Participate in the Morgan..
8/23/202316:08GLOBECentessa Pharmaceuticals to Present Preclinical Data for..
8/14/202306:18EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Your Recent History

NASDAQ
CNTA
Centessa Pharmaceuticals
BIT
UIK009
UniCredit Bank
NASDAQ
TREHX
T Rowe Price Retirement ...
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved